Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
Completed · Phase 2
Conditions studied: Myelogenous Leukemia, Chronic
In brief
The goal of this research is to see if giving the drug SCH66336 by mouth can improve the disease in patients with chronic or accelerated phase CML. The safety of this treatment will also be studied.
Key facts
- Study ID
- NCT00038597
- Run by
- M.D. Anderson Cancer Center
- People needed
- 13
- Starts
- 2001-04-30
- Expected to finish
- 2004-05-07
- Last updated by the study team
- 2018-10-30
Who can join
Age: 16 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- MDAnderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.